

Xuezhi Cao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4120568/publications.pdf>

Version: 2024-02-01

14
papers

1,012
citations

759233

12
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

1720
citing authors

#	ARTICLE	IF	CITATIONS
1	Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein β Signaling. <i>Immunity</i> , 2017, 47, 363-373.e5.	14.3	209
2	Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity. <i>Journal of Hepatology</i> , 2013, 59, 52-58.	3.7	157
3	DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. <i>Cancer Cell</i> , 2021, 39, 96-108.e6.	16.8	153
4	MDA5 plays a critical role in interferon response during hepatitis C virus infection. <i>Journal of Hepatology</i> , 2015, 62, 771-778.	3.7	83
5	Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling. <i>Nature Immunology</i> , 2020, 21, 546-554.	14.5	78
6	Identification of Cholesterol 25-Hydroxylase as a Novel Host Restriction Factor and a Part of the Primary Innate Immune Responses against Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2015, 89, 6805-6816.	3.4	76
7	A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy. <i>Nature Communications</i> , 2021, 12, 2768.	12.8	62
8	Negative Regulation of Interferon-induced Transmembrane Protein 3 by SET7-mediated Lysine Monomethylation. <i>Journal of Biological Chemistry</i> , 2013, 288, 35093-35103.	3.4	41
9	Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. <i>Nature Communications</i> , 2021, 12, 5866.	12.8	39
10	Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	35
11	Hepatitis C virus NS4B induces the degradation of TRIF to inhibit TLR3-mediated interferon signaling pathway. <i>PLoS Pathogens</i> , 2018, 14, e1007075.	4.7	32
12	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells. <i>Cell Reports Medicine</i> , 2022, 3, 100554.	6.5	29
13	Neutralized E3 Ubiquitin Protein Ligase 3 Is an Inducible Antiviral Effector That Inhibits Hepatitis C Virus Assembly by Targeting Viral E1 Glycoprotein. <i>Journal of Virology</i> , 2018, 92, .	3.4	11
14	AXL targeting with bemcentinib restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells. , 2021, 9, A632-A632.		0